These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12517255)

  • 1. Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future.
    Farvolden P; Kennedy SH; Lam RW
    Expert Opin Investig Drugs; 2003 Jan; 12(1):65-86. PubMed ID: 12517255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs in development for social anxiety disorder: more to social anxiety than meets the SSRI.
    van Ameringen M; Mancini C; Farvolden P; Oakman J
    Expert Opin Investig Drugs; 2000 Oct; 9(10):2215-31. PubMed ID: 11060802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.
    Bymaster FP; McNamara RK; Tran PV
    Expert Opin Investig Drugs; 2003 Apr; 12(4):531-43. PubMed ID: 12665410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kynurenine pathway dysfunction in the pathophysiology and treatment of depression: Evidences from animal and human studies.
    Réus GZ; Jansen K; Titus S; Carvalho AF; Gabbay V; Quevedo J
    J Psychiatr Res; 2015 Sep; 68():316-28. PubMed ID: 26028548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters.
    Haenisch B; Bönisch H
    Pharmacol Ther; 2011 Mar; 129(3):352-68. PubMed ID: 21147164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging drugs for major depressive disorder.
    Connolly KR; Thase ME
    Expert Opin Emerg Drugs; 2012 Mar; 17(1):105-26. PubMed ID: 22339643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 5-HT
    Tiger M; Varnäs K; Okubo Y; Lundberg J
    Psychopharmacology (Berl); 2018 May; 235(5):1317-1334. PubMed ID: 29546551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopaminergic-based pharmacotherapies for depression.
    Papakostas GI
    Eur Neuropsychopharmacol; 2006 Aug; 16(6):391-402. PubMed ID: 16413172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depression and renal disease.
    Tossani E; Cassano P; Fava M
    Semin Dial; 2005; 18(2):73-81. PubMed ID: 15771649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New approaches to the pharmacological management of major depressive disorder.
    Witkin JM; Li X
    Adv Pharmacol; 2009; 57():347-79. PubMed ID: 20230766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C; Wang SM; Kato M; Lee SJ; Patkar AA; Masand PS; Pae CU
    Expert Rev Neurother; 2013 Jul; 13(7):851-70. PubMed ID: 23898855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational site-directed pharmacotherapy for major depressive disorder.
    Blier P
    Int J Neuropsychopharmacol; 2014 Jul; 17(7):997-1008. PubMed ID: 23745670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The promise of ketamine for treatment-resistant depression: current evidence and future directions.
    DeWilde KE; Levitch CF; Murrough JW; Mathew SJ; Iosifescu DV
    Ann N Y Acad Sci; 2015 May; 1345(1):47-58. PubMed ID: 25649308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic NMDA Receptor as Therapeutic Target for Depression.
    Réus GZ; Abelaira HM; Tuon T; Titus SE; Ignácio ZM; Rodrigues AL; Quevedo J
    Adv Protein Chem Struct Biol; 2016; 103():169-202. PubMed ID: 26920690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions targeting anhedonia in patients with major depressive disorder: A systematic review.
    Cao B; Zhu J; Zuckerman H; Rosenblat JD; Brietzke E; Pan Z; Subramanieapillai M; Park C; Lee Y; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():109-117. PubMed ID: 30611836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants.
    Chang HS; Won E; Lee HY; Ham BJ; Lee MS
    Behav Brain Res; 2015 Oct; 292():116-24. PubMed ID: 26055202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cellular and molecular basis of major depressive disorder: towards a unified model for understanding clinical depression.
    Pitsillou E; Bresnehan SM; Kagarakis EA; Wijoyo SJ; Liang J; Hung A; Karagiannis TC
    Mol Biol Rep; 2020 Jan; 47(1):753-770. PubMed ID: 31612411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive remission: a novel objective for the treatment of major depression?
    Bortolato B; Miskowiak KW; Köhler CA; Maes M; Fernandes BS; Berk M; Carvalho AF
    BMC Med; 2016 Jan; 14():9. PubMed ID: 26801406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.